Hikma Pharmaceuticals Plc Holding(s) in Company (6832G)
November 24 2015 - 2:02AM
UK Regulatory
TIDMHIK
RNS Number : 6832G
Hikma Pharmaceuticals Plc
24 November 2015
Notification of major interests in shares
LONDON, 24 November 2015 - Hikma Pharmaceuticals PLC ("Hikma")
(LSE: HIK) (DIFX: HIK), the fast growing multinational
pharmaceuticals group, announces as follows:
1 Identity of the issuer or the underlying Hikma Pharmaceuticals PLC
issuer of existing shares to which the
voting rights are attached
2 Reason for the notification
An acquisition or disposal of voting rights Yes
--------------------------------------------------------- ----
An acquisition or disposal of financial instruments No
which may result in the acquisition of shares already
issues to which voting rights are attached
--------------------------------------------------------- ----
An event changing the breakdown of voting rights No
--------------------------------------------------------- ----
Other (please specify): Compliance with the Transparency No
Directive
--------------------------------------------------------- ----
3 Full name of the person subject to the FMR LLC
notification obligation
4 Full name of shareholders See Section 9
--------------------------------------------------------------- -------------------------------------
5 Date of the Transaction (and date on 17(th) November 2015
which the threshold crossed is reached
differently)
--------------------------------------------------------------- -------------------------------------
6 Date on which the issuer notified 23(rd) November 2015
--------------------------------------------------------------- -------------------------------------
7 Threshold that is crossed 5%
--------------------------------------------------------------- -------------------------------------
8 Notified details See A, B & C below
----- --------------------------------------------------------------- -------------------------------------
A. Voting rights attached to shares
Class type Situation previous Resulting situation after the triggering
of shares to the triggering transaction
(if possible transaction
using the
ISIN code)
------------------------ -----------------------------------------------------------------
Number Number Number of shares Number of voting % of voting
of shares of voting rights rights
rights
----------- ----------- ------------------- --------------------- ---------------------
Direct Indirect Direct Indirect Direct Indirect
----------- ----------- ------- ---------- --------- ---------- ------- ------------
Ordinary
Shares (0.10
GBP)
GB00B0LCW083 10,071,182 10,071,182 9,791,950 9,791,950 4.91%
----------- ----------- ------- ---------- --------- ---------- ------- ------------
B. Qualifying Financial instruments
Resulting situation after the triggering transaction
Type of financial Expiration Exercise/Conversion Number of voting % of voting rights
instrument Date Period/Date rights that may
be acquired if
the instrument
if exercised/converted
----------- -------------------- ------------------------ -------------------
- - - - -
----------- -------------------- ------------------------ -------------------
C: Financial Instruments with similar economic effect to Qualifying
Financial Instruments
Resulting situation after the triggering transaction
Type of Exercise Expiration Exercise/Conversion Number of voting % of voting rights
financial Price Date Period/Date rights instrument
instrument refers to
--------- ----------- -------------------- ------------------- ---------------------
Nominal Delta
--------- ----------- -------------------- ------------------- ----------- --------
- - - - - - -
--------- ----------- -------------------- ------------------- ----------- --------
Total A+B+C
Number of Voting rights % of voting rights
-------------------
9,791,950 4.91
-------------------
9 Chain of controlled undertakings through which the voting rights
and/or the financial instruments are effectively held, if applicable
Custodian Day to Day IM Total
BANK OF NEW YORK BRUSSELS (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 5,244
BANK OF NEW YORK MELLON PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 116,750
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS
BNP PARIBAS SEC SVCS LONDON TRUST COMPANY 45,902
BROWN BROS HARRIMN LTD LUX (C) FMRC-FMR CO., INC 563
BROWN BROTHERS HARRIMAN AND CO FMRC-FMR CO., INC 68,146
FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED 44,975
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 55,245
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 537,558
CIBC MELLON TRUST (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 13,333
CITIBANK NA, HONG KONG BR (S) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 16,382
JP MORGAN, BOURNEMOUTH (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 9,809
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 113,142
JPMORGAN CHASE BANK FMRC-FMR CO., INC 3,912,987
FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED 151,087
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 34,638
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 54,815
MELLON BANK NA (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 259,991
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 72,600
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS
NATIONAL BANK TRUST (C) TRUST COMPANY 14,829
NOMURA TRUST AND BANKING (C) PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 553
NORTHERN TRUST CO (C) FMRC-FMR CO., INC 207,323
FMRIMUK-FMR INVESTMENT MANAGEMENT (UK) LIMITED 2,598,333
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 36,157
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 272,510
STATE STREET BANK AND TR CO FMRC-FMR CO., INC 296,940
PGALLC-PYRAMIS GLOBAL ADVISORS, LLC 470,644
PYRAMIS GLOBAL-PYRAMIS GLOBAL ADVISORS TRUST COMPANY 381,494
Grand Total 9,791,950
---------------------------------------------------------------------------------------------
Proxy Voting
10 Name of the proxy holder FMR LLC
-------------------------------------- ---------------------
Number of voting rights proxy holder
11 will cease to hold: 279,232
-------------------------------------- ---------------------
12 Date on which proxy holder will cease 17(th) November 2015
to hold voting rights:
-------------------------------------- ---------------------
13 Additional Information
14 Contact name: Peter Speirs, Company Secretary
-------------------------- --------------------------------
15 Contact telephone number: 020 7399 2772
-------------------------- --------------------------------
- ENDS -
About Hikma
Hikma Pharmaceuticals PLC is a fast growing pharmaceutical group
focused on developing, manufacturing and marketing a broad range of
both branded and non-branded generic and in-licensed products.
Hikma's operations are conducted through three businesses:
"Branded", "Injectables" and "Generics" based primarily in the
Middle East and North Africa ("MENA") region, where it is a market
leader, the United States and Europe. In 2014, Hikma achieved
revenues of $1,489 million and profit attributable to shareholders
of $278 million.
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUOUBRVVAAUAA
(MORE TO FOLLOW) Dow Jones Newswires
November 24, 2015 02:02 ET (07:02 GMT)
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jun 2024 to Jul 2024
Hikma Pharmaceuticals (LSE:HIK)
Historical Stock Chart
From Jul 2023 to Jul 2024
